A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

NCT05199584 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors With PTCH1 Loss-of-function Mutations

Interventions

DRUG: ENV-101 (taladegib)

Sponsor

Endeavor Biomedicines, Inc.